These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17235522)

  • 21. Glucose or intermittent high-intensity exercise in glargine/glulisine users with T1DM.
    Dubé MC; Lavoie C; Weisnagel SJ
    Med Sci Sports Exerc; 2013 Jan; 45(1):3-7. PubMed ID: 22895370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.
    Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H
    J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
    Butler PC
    Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin.
    Kara C; Kutlu AO; Evliyaoglu O; Bilgili H; Yildirim N
    Diabetes Care; 2005 Apr; 28(4):983-4. PubMed ID: 15793215
    [No Abstract]   [Full Text] [Related]  

  • 27. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin glargine.
    Am J Health Syst Pharm; 2000 Nov; 57(21):1960-1. PubMed ID: 11094649
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
    Pedersen-Bjergaard U; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):553-61. PubMed ID: 24794703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus.
    Dixon AN; Bain SC
    BMJ; 2005 Feb; 330(7489):455. PubMed ID: 15731143
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety.
    Buse J
    Diabetes Care; 2000 May; 23(5):576-8. PubMed ID: 10834411
    [No Abstract]   [Full Text] [Related]  

  • 33. [Flexible intensive insulin therapy: a change in mentalities].
    Penfornis A; Chabroux S; Grimaldi A
    Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of insulin glargine during pregnancy in seven type 1 diabetic women.
    Woolderink JM; van Loon AJ; Storms F; de Heide L; Hoogenberg K
    Diabetes Care; 2005 Oct; 28(10):2594-5. PubMed ID: 16186314
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial: glargine, a new long-acting insulin analog for diabetic cats.
    Rand J
    J Vet Intern Med; 2006; 20(2):219-20. PubMed ID: 16594574
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin analogues for type 1 diabetes in children and adolescents.
    Galli-Tsinopoulou A; Stergidou D
    Drugs Today (Barc); 2012 Dec; 48(12):795-809. PubMed ID: 23243636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No evidence for accumulation of insulin glargine (LANTUS).
    Biermann E
    Diabet Med; 2003 Apr; 20(4):333-4; author reply 334-5. PubMed ID: 12675652
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life.
    Bohannon NJ
    Postgrad Med; 2003 Jun; 113(6):39-42, 45-8, 54. PubMed ID: 12838803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.